NeoZanHER phase 2 trial results published in Nature Communications are spotlighting zanidatamab in early-stage HER2-positive breast cancer, evaluating the next-generation bispecific antibody before surgery. The trial is designed to assess how treating earlier in the disease course can shift response patterns in a curative setting. Zanidatamab is built to engage HER2 with dual mechanisms, aiming to increase immune-mediated and receptor-blocking activity. As a preoperative strategy, the study’s endpoints are structured around response in the breast and pathologic outcomes that can influence subsequent management. The development is directly relevant to the competitive HER2 landscape, where multiple antibody-based approaches are being tested for neoadjuvant use and to improve the depth of response. The update extends the move toward more aggressive, earlier immuno-oncology integration in HER2-positive disease to potentially reduce residual disease after standard-of-care surgery.